文献速递糖尿病

心包腔局部IGF生物活性与PAPP-A活性升高相关

Local IGF Bioactivity Associates with High PAPP-A Activity in the Pericardial Cavity of Cardiovascular Disease Patients.
PubMed 文献 · J Clin Endocrinol Metab · 2020-01-01

该研究纳入39例择期心胸手术患者(其中15例2型糖尿病),比较心包液与血浆中IGF系统相关蛋白及生物活性。心包液中PAPP-A浓度是血浆的15倍,IGFBP-4片段升高超过25%,IGF生物活性较血浆高62±81%。提示PAPP-A通过切割IGFBP-4增强心包腔局部IGF活性。

要点

  • 心包液中PAPP-A浓度是血浆的15倍,IGF生物活性较血浆高62±81%。
  • 心包液中总IGF-I、完整IGFBP-4和STC2分别较血浆低72±10%、91±5%和40±24%。
  • IGFBP-4片段与PAPP-A浓度及IGF生物活性相关,糖尿病与非糖尿病者心包液蛋白水平相似。

核心结论

  • PAPP-A通过切割IGFBP-4增加心血管疾病患者心包腔内的IGF生物活性。
  • 研究提示IGF系统存在局部活性,可能促进心功能障碍和冠状动脉粥样硬化。

研究设计与样本

  • 研究纳入39例择期心胸手术患者,其中15例为2型糖尿病。
  • 获取血浆和心包液,用免疫分析法测定IGF-I、完整和片段化IGFBP-4、PAPP-A和STC2,用细胞分析法测定IGF生物活性。

主要发现

  • 心包液中总IGF-I、完整IGFBP-4和STC2浓度分别较血浆低72±10%、91±5%和40±24%。
  • 心包液中PAPP-A浓度是血浆的15倍,PAPP-A生成的2种IGFBP-4片段水平升高超过25%。
  • 心包液IGF生物活性较血浆高62±81%,两种IGFBP-4片段水平均与PAPP-A浓度及IGF生物活性相关。
  • 非糖尿病与糖尿病受试者心包液中所有蛋白水平相似。

临床怎么用

  • 需认识心血管疾病患者心包腔存在独立的IGF系统局部活性,PAPP-A是关键调节酶。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Pregnancy-associated plasma protein-A (PAPP-A) has been suggested as a proatherogenic enzyme by its ability to locally increase insulin-like growth factor (IGF) activity through proteolytic cleavage of IGF binding protein-4 (IGFBP-4). Recently, stanniocalcin-2 (STC2) was discovered as an inhibitor of PAPP-A. This study aimed to investigate IGFBP-4, PAPP-A, and STC2 as local regulators of IGF bioactivity in the cardiac microenvironment by comparing levels in the pericardial fluid with those in the circulation of patients with cardiovascular disease. METHODS: Plasma and pericardial fluid were obtained from 39 patients undergoing elective cardiothoracic surgery, hereof 15 patients with type 2 diabetes. Concentrations of IGF-I, intact and fragmented IGFBP-4, PAPP-A, and STC2 were determined by immunoassays and IGF bioactivity by a cell-based assay. RESULTS: In pericardial fluid, the concentrations of total IGF-I, intact IGFBP-4, and STC2 were 72 ± 10%, 91 ± 5%, and 40 ± 24% lower than in plasma, while PAPP-A was 15 times more concentrated. The levels of the 2 IGFBP-4 fragments generated by PAPP-A and reflecting PAPP-A activity were elevated by more than 25%. IGF bioactivity was 62 ± 81% higher in the pericardial fluid than plasma. Moreover, pericardial fluid levels of both IGFBP-4 fragments correlated with the concentration of PAPP-A and with the bioactivity of IGF. All protein levels were similar in pericardial fluid from nondiabetic and diabetic subjects. CONCLUSIONS: PAPP-A increases IGF bioactivity by cleavage of IGFBP-4 in the pericardial cavity of cardiovascular disease patients. This study provides evidence for a distinct local activity of the IGF system, which may promote cardiac dysfunction and coronary atherosclerosis.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Hjortebjerg R, Rasmussen LM, Gude MF, et al. Local IGF Bioactivity Associates with High PAPP-A Activity in the Pericardial Cavity of Cardiovascular Disease Patients. J Clin Endocrinol Metab. 2020. PMID: 32875328. doi:10.1210/clinem/dgaa617

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。